Zobrazeno 1 - 10
of 60
pro vyhledávání: '"Benzimidazoles/administration '
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Leticia Norma Carpentieri Rodrigues, Anna Carollina Moraes Tavares, Beatriz Tavares Ferreira, Adriana Karla Cardoso Amorim Reis, Luciana Morita Katiki
Publikováno v:
Brazilian Journal of Pharmaceutical Sciences, Vol 55 (2019)
Albendazole and fenbendazole are imidazole derivatives that exhibit broad spectrum activity against parasites, but the low solubility of these drugs considerably reduces their effectiveness. Complexation of albendazole and fenbendazole with cyclodext
Externí odkaz:
https://doaj.org/article/c1965d5147ed460f8d9e56c03006feb1
Autor:
Axel Grothey, Sara Lonardi, Victor Sandor, Neeltje Steeghs, Rona Yaeger, Elena Elez, Yong Sang Hong, Harpreet Wasan, Christina Guo, Jan H.M. Schellens, Tae Won Kim, Eric Van Cutsem, Ashwin Gollerkeri, Tormod Kyrre Guren, Fotios Loupakis, Line Schmidt Tarpgaard, Kati Maharry, Jayesh Desai, Lisa Anderson, Sergey Orlov, Aitana Calvo Ferrándiz, Jeroen Dekervel, Michael Braun, Per Pfeiffer, Asha Krishnan, Pilar García-Alfonso, Michael D Pickard, Scott Kopetz, Janna Christy-Bittel, Hendrik Tobias Arkenau, Takayuki Yoshino, Fortunato Ciardiello, Christopher Hunt Keir, Van Morris, Josep Tabernero
Publikováno v:
Kopetz, S, Grothey, A, Yaeger, R, Van Cutsem, E, Desai, J, Yoshino, T, Wasan, H, Ciardiello, F, Loupakis, F, Hong, Y S, Steeghs, N, Guren, T K, Arkenau, H T, Garcia-Alfonso, P, Pfeiffer, P, Orlov, S, Lonardi, S, Elez, E, Kim, T W, Schellens, J H M, Guo, C, Krishnan, A, Dekervel, J, Morris, V, Ferrandiz, A C, Tarpgaard, L S, Braun, M, Gollerkeri, A, Keir, C, Maharry, K, Pickard, M, Christy-Bittel, J, Anderson, L, Sandor, V & Tabernero, J 2019, ' Encorafenib, binimetinib, and cetuximab in BRAF V600E–mutated colorectal cancer ', New England Journal of Medicine, vol. 381, no. 17, pp. 1632-1643 . https://doi.org/10.1056/NEJMoa1908075
BACKGROUND: Patients with metastatic colorectal cancer with the BRAF V600E mutation have a poor prognosis, with a median overall survival of 4 to 6 months after failure of initial therapy. Inhibition of BRAF alone has limited activity because of path
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::80ce4d5efea909032075f515edc5b20a
https://doi.org/10.1056/nejmoa1908075
https://doi.org/10.1056/nejmoa1908075
Autor:
TG Snider, JC Williams
Publikováno v:
Veterinary Record. 106:34-34
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ad6d936fe3dd3c95ec2e6a4a0f95c943
https://doi.org/10.1136/vr.106.2.34
https://doi.org/10.1136/vr.106.2.34
Autor:
Luciana Morita Katiki, Leticia Norma Carpentieri Rodrigues, Beatriz Tavares Ferreira, Adriana Karla Cardoso Amorim Reis, Anna Carollina Moraes Tavares
Publikováno v:
Brazilian Journal of Pharmaceutical Sciences, Volume: 55, Article number: e17776, Published: 25 NOV 2019
Brazilian Journal of Pharmaceutical Sciences, Vol 55 (2019)
Brazilian Journal of Pharmaceutical Sciences; Vol. 55 (2019); e17776
Brazilian Journal of Pharmaceutical Sciences; v. 55 (2019); e17776
Brazilian Journal of Pharmaceutical Sciences
Universidade de São Paulo (USP)
instacron:USP
Brazilian Journal of Pharmaceutical Sciences, Vol 55 (2019)
Brazilian Journal of Pharmaceutical Sciences; Vol. 55 (2019); e17776
Brazilian Journal of Pharmaceutical Sciences; v. 55 (2019); e17776
Brazilian Journal of Pharmaceutical Sciences
Universidade de São Paulo (USP)
instacron:USP
Albendazole and fenbendazole are imidazole derivatives that exhibit broad spectrum activity against parasites, but the low solubility of these drugs considerably reduces their effectiveness. Complexation of albendazole and fenbendazole with cyclodext
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6ee9b7101822daebb02ffd1bf7d232e7
http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1984-82502019000100551&lng=en&tlng=en
http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1984-82502019000100551&lng=en&tlng=en
Publikováno v:
Bøttcher, T M, Cold, S & Jensen, A B 2019, ' Treatment of advanced HR+/HER2− breast cancer with new targeted agents in combination with endocrine therapy : a review of efficacy and tolerability based on available randomized trials on everolimus, ribociclib, palbociclib and abemaciclib ', Acta Oncologica, vol. 58, no. 2, pp. 147-153 . https://doi.org/10.1080/0284186X.2018.1532603
Bøttcher, T M, Cold, S & Jensen, A B 2019, ' Treatment of advanced HR+/HER2-breast cancer with new targeted agents in combination with endocrine therapy: a review of efficacy and tolerability based on available randomized trials on everolimus, ribociclib, palbociclib and abemaciclib ', Acta Oncologica, vol. 58, no. 2, pp. 147-153 . https://doi.org/10.1080/0284186X.2018.1532603
Bøttcher, T M, Cold, S & Jensen, A B 2019, ' Treatment of advanced HR+/HER2-breast cancer with new targeted agents in combination with endocrine therapy: a review of efficacy and tolerability based on available randomized trials on everolimus, ribociclib, palbociclib and abemaciclib ', Acta Oncologica, vol. 58, no. 2, pp. 147-153 . https://doi.org/10.1080/0284186X.2018.1532603
Introduction: Recently, new targeted agents have been developed, which can prolong the effect of endocrine treatment (ET) by targeting resistance pathways in HR+/HER2− advanced breast cancer. This review examines available studies of everolimus, an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::daa0942932052480a705d1f354fa46e9
https://pubmed.ncbi.nlm.nih.gov/30375908
https://pubmed.ncbi.nlm.nih.gov/30375908
Autor:
Shannon Puhalla, M. Friedlander, Igor Bondarenko, Caroline Nickner, Qin Qin, Steven J. Isakoff, Paul K. Marcom, M. Campone, Erik Jakobsen, Judy Garber, E. Chmielowska, M Palácová, Christine K. Ratajczak, H.S. Han, William J. Gradishar, Melinda L. Telli, Mark E. Robson, Jane Qian, Agnes Jager, Susan M. Domchek, D Citrin, Virginia G. Kaklamani, Yaroslav Shparyk, Stacie Peacock Shepherd, Bella Kaufman, Véronique Diéras
Publikováno v:
Annals of Oncology, 29(1), 154-161. Elsevier Ltd.
Han, H S, Diéras, V, Robson, M, Palácová, M, Marcom, P K, Jager, A, Bondarenko, I, Citrin, D, Campone, M, Telli, M L, Domchek, S M, Friedlander, M, Kaufman, B, Garber, J E, Shparyk, Y, Chmielowska, E, Jakobsen, E H, Kaklamani, V, Gradishar, W, Ratajczak, C K, Nickner, C, Qin, Q, Qian, J, Shepherd, S P, Isakoff, S J & Puhalla, S 2018, ' Veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in patients with BRCA1/2 locally recurrent/metastatic breast cancer : Randomized phase II study ', Annals of Oncology, vol. 29, no. 1, pp. 154-161 . https://doi.org/10.1093/annonc/mdx505
Han, H S, Diéras, V, Robson, M, Palácová, M, Marcom, P K, Jager, A, Bondarenko, I, Citrin, D, Campone, M, Telli, M L, Domchek, S M, Friedlander, M, Kaufman, B, Garber, J E, Shparyk, Y, Chmielowska, E, Jakobsen, E H, Kaklamani, V, Gradishar, W, Ratajczak, C K, Nickner, C, Qin, Q, Qian, J, Shepherd, S P, Isakoff, S J & Puhalla, S 2018, ' Veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in patients with BRCA1/2 locally recurrent/metastatic breast cancer : Randomized phase II study ', Annals of Oncology, vol. 29, no. 1, pp. 154-161 . https://doi.org/10.1093/annonc/mdx505
Background: Homologous recombination defects in BRCA1/2-mutated tumors result in sensitivity to poly(ADP-ribose) polymerase inhibitors, which interfere with DNA damage repair. Veliparib, a potent poly(ADP-ribose) polymerase inhibitor, enhanced the an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e6245faf8fe340df6bb665b1a1db5b1a
https://pure.eur.nl/en/publications/f335467b-a340-4640-9706-dda834d92443
https://pure.eur.nl/en/publications/f335467b-a340-4640-9706-dda834d92443
Autor:
Carrieri, Maria Patrizia, Protopopescu, Camelia, Younossi, Zobair, Vilotitch, Antoine, Fontaine, Hélène, Petrov-Sanchez, Ventzislava, Marcellin, Fabienne, Carrat, Fabrice, Hézode, Christophe, Bourlière, Marc, Poncin, Eric, Botta-Friedland, Danièle, Fontanges, Thierry, Arpurt, Jean-Pierre, Bacq, Yannicq, Calès, Paul, Delasalle, Patrick, Ouzan, Denis, Nousbaum, Jean-Baptiste, Sylvain, Christine, Ribard, Didier, Gatineau-Sailliant, Gilles, de Montigny-Lenhardt, Stéphanie, Renard, Philippe, Pilette, Christophe, Denis, Jacques, Lascoux-Combe, Caroline, Abel, Laurent, Albert, Matthew, Chazouillères, Olivier, Dubuisson, Jean, Negro, Francesco, Pageaux, Georges-Philippe, Paradis, Valérie, Spire, Bruno, Taburet, Anne-Marie, Trinchet, Jean-Claude, Yazdanpanah, Yazdan, Dufour, Cécilie, Fréhaut, Céline, Pirot, Marion, Lesel, Aurélie, Zahraa, Nathalie, Chau, Frédéric
Publikováno v:
The Patient-Patient-Centered Outcomes Research
The Patient-Patient-Centered Outcomes Research, 2017, 10 (5), pp.605-614. ⟨10.1007/s40271-017-0232-1⟩
The Patient-Patient-Centered Outcomes Research, Vol. 10, No 5 (2017) pp. 605-614
The Patient-Patient-Centered Outcomes Research, 2017, 10 (5), pp.605-614. ⟨10.1007/s40271-017-0232-1⟩
The Patient-Patient-Centered Outcomes Research, Vol. 10, No 5 (2017) pp. 605-614
International audience; Objective We aimed to compare health-related quality of life (HRQL) during and after HCV treatment in patients receiving pegylated-interferon (PEG-IFN)-containing therapy (including boceprevir or telaprevir - ANRS CO20 CUPIC c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0ff9a9084dace7c7dc34a62f21b4933e
https://hal.science/hal-01767765/document
https://hal.science/hal-01767765/document
Publikováno v:
Clinics in Laboratory Medicine. 34(3):479-501
Dabigatran, a direct thrombin inhibitor, is increasingly used clinically as one of the new oral anticoagulants. This review summarizes the assays available to measure its activity and includes the relative sensitivity of the different assays for this
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od________83::a5a948e7ba62be94612584e2c073b537
https://cris.maastrichtuniversity.nl/en/publications/d2a862fd-eadb-4d66-b543-dfafda6eb760
https://cris.maastrichtuniversity.nl/en/publications/d2a862fd-eadb-4d66-b543-dfafda6eb760
Autor:
Grzegorz Bilo, Sergio Caravita, Piergiuseppe Agostoni, José Luis Macarlupú, Cecilia Anza-Ramirez, Francisco C. Villafuerte, Morin Lang, Elisabetta Salvioni, Andrea Faini, Gianfranco Parati
Background: Limited evidence exists on blood pressure (BP) responses to exercise in hypertensive subjects exposed to high altitude, and on the effects of antihypertensive treatment in this setting. We aimed to asses BP response to submaximal exercise
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bd8b1c031aa5ca0b2d83dda91f7a053b
http://hdl.handle.net/10446/188872
http://hdl.handle.net/10446/188872